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Objectives. This study sought to examine plasma levels of
soluble Fas/APO-1 receptor (sFas), an inhibitor of apoptosis, and
soluble Fas ligand (sFas-L), an inducer of apoptosis, and their
relation to each other and to other clinical variables, such as New
York Heart Association functional class, tumor necrosis factor
(TNF) and interleukin-6 (IL-6) in congestive heart failure (CHF).
Background. It has been recently reported that apoptotic cell
death occurs in myocytes of dogs with CHF. Hypoxia is frequently
seen in advanced CHF and can stimulate Fas/APO-1 receptors (Fas)
to induce apoptosis in cultured myocytes. Fas and Fas ligand (Fas-L)
are cell-surface proteins and representative apoptosis-signaling mol-
ecules. Fas on the cell membrane induces apoptosis when it binds
Fas-L or sFas-L. However, plasma sFas, a molecule lacking the
transmembrane domain of Fas, blocks apoptosis by inhibiting bind-
ing between Fas and Fas-L or sFas-L on the cell membrane. At
present, it is unknown whether plasma sFas-L and plasma sFas
increase in the presence of cardiac disease.
Methods. The study included 70 patients (mean [6SEM] age 65 6
2 years, range 21 to 93) with chronic CHF (coronary artery disease in
28, dilated cardiomyopathy in 27, valvular heart disease in 15) and 62
age- and gender-matched normal control subjects. Plasma levels of
sFas, sFas-L, TNF-alpha and IL-6 were measured by enzyme-linked
immunosorbent assays using monoclonal anti-human antibodies.
Results. There was no significant difference in sFas-L levels
between normal subjects and patients in functional classes I to IV;
however, sFas increased with severity of functional classification,
independent of the underlying disease. sFas levels were signifi-
cantly higher even in patients in functional class II than in normal
subjects and those in functional class I, and were highest in
patients in functional class IV (normal subjects: 2.2 6 0.1 ng/ml;
functional class I: 2.2 6 0.2 ng/ml; functional class II: 3.1 6
0.2 ng/ml; functional class III: 3.9 6 0.3 ng/ml; functional class IV:
5.1 6 0.6 ng/ml). Plasma sFas levels were significantly higher in
patients with elevated pulmonary artery wedge pressure and a
decreased cardiac index than in those with values in the normal
range. In patients in functional class IV, there was no significant
difference in plasma sFas levels between the survivors and non-
survivors during 6-month follow-up. However, plasma levels of
sFas tended to decrease in nine patients with clinical improve-
ment (baseline sFas: 5.2 6 0.8 ng/ml; 6-month sFas: 4.3 6
0.5 ng/ml, p 5 0.07) but were similar in patients with no change in
functional class. TNF-alpha and IL-6 were increased significantly
only in patients in functional class IV, as previously reported, but
were not related to sFas.
Conclusions. We found elevated levels of plasma sFas and no
increase in plasma sFas-L in human CHF. The increase in sFas
may play an important role in the pathophysiologic mechanisms
of CHF.
(J Am Coll Cardiol 1997;29:1214–20)
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Apoptosis, or programmed cell death, was recognized by Kerr
(1) as a distinctive morphologic entity that he called “shrinkage
necrosis.” Kerr et al. (2) then provided evidence of apoptosis
as a basic biologic phenomenon with wide-ranging implications
in tissue kinetics. Apoptosis differs from necrosis in terms of
ultrastructural and biochemical features, which include cyto-
plasmic and nuclear condensation, subsequent formation of
membrane-bound apoptotic bodies (segmentation of the nu-
cleus) and extensive degeneration of chromosomal DNA into
oligomers of ;180 base pairs caused by activation of endoge-
nous endonuclease (3–6). Apoptosis is not characteristically
associated with inflammatory cell infiltration, unlike necrosis
(7). It has been reported (8–10) that apoptosis in myocytes is
induced by postnatal morphogenesis, especially in the conduc-
tion system, and by hypoxia and reperfusion after ischemia.
Recently, Sharov et al. (11) found morphologic and histologic
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evidence of myocyte apoptosis in the left ventricular myocar-
dium of dogs with congestive heart failure (CHF). Hypoxia,
which can occur in advanced CHF, can induce apoptosis in
cultured myocytes and liver cells (9,12,13). However, the
relation between apoptosis and CHF is still unclear in humans.
At present, there are many inducers and inhibitors of
apoptosis. The inducers of apoptosis, such as tumor necrosis
factor (TNF)-alpha, a TNF family, and interleukin 6 (IL-6), a
cytokine-inducing transcription of the Fas/APO-1 receptor
(Fas) gene, are increased in the plasma of patients with severe
CHF (14–17). We recently reported (12) that Bax, an inducer
of apoptosis, was expressed in the myocytes of autopsied
human hearts with an old myocardial infarction and in most of
which CHF was present (12). The Fas–Fas ligand (Fas-L)
system is the representative system of apoptosis-signaling
receptor molecules. Fas (CD95) is a cell surface protein
consisting of 319 amino acids with a single transmembrane
domain, belonging to the nerve growth factor receptor/TNF
receptor family (type I membrane protein) (18–22). Molecular
cloning and nucleotide sequence analysis have revealed a
human Fas messenger RNA variant that encodes a soluble Fas
(sFas) molecule lacking the transmembrane domain because of
the deletion of an exon encoding this region (23). sFas (soluble
form of Fas) is found in the culture supernatants of different
human B- and T-cell lines (24). Fas-L is a type II membrane
protein that belongs to the TNF family (22,25,26). Membrane-
bound human Fas-L is converted to a soluble form by a matrix
metalloproteinase-like enzyme (27,28). Human soluble Fas
ligand (sFas-L), a 26-kDa glycoprotein, consists of the extra-
cellular region of the Fas-L. Fas-L is predominantly expressed
in activated T cells, whereas Fas is expressed in various tissues,
including the thymus, heart, liver and ovary but not in the brain
or spleen in mice (29,30). Binding of Fas-L, sFas-L or agonistic
anti-Fas antibodies to Fas induces apoptosis (26,29,30). How-
ever, extrinsic sFas blocks apoptosis in cells by inhibiting the
binding of the Fas-L or sFas-L to Fas on the cell membrane
(23,31). Recently, it has been reported that sFas is elevated in
the serum of patients with B- and T-cell leukemias and
systemic lupus erythematosus (23,24), as are sFas-L levels in
patients with large granular lymphocytic leukemia and natural
killer cell lymphoma (31). A recent report (9) showed that Fas
messenger RNA is induced by hypoxia in cultured neonatal rat
myocytes. However, whether plasma levels of sFas and sFas-L
are elevated in patients with CHF remains unknown.
The present study was designed to assess 1) whether the
plasma concentrations of sFas, an inhibitor of apoptosis, and
sFas-L, an inducer of apoptosis, increase with New York Heart
Association functional class in patients with CHF; and 2)
whether they are related to other clinical variables such as
hemodynamic data. Plasma levels of TNF-alpha and IL-6,
which are elevated in patients with severe CHF and are
Fas–Fas-L system-related factors (13–16), were also measured
and compared with plasma levels of sFas-L and sFas.
Methods
Subjects. Seventy patients (mean [6SEM] 65 6 2 years,
range 21 to 93) with chronic CHF (coronary artery disease in
36, dilated cardiomyopathy in 24, valvular heart disease in 10)
were diagnosed by physical examination, echocardiography
and cardiac catheterization (Table 1). Patients with significant
concomitant diseases, such as pulmonary disease, malignancy,
autoimmune disorders, neurodegenerative disorders, diabetes
mellitus, thyroid disease or concurrent viral disease, were
excluded from the study. Patients were grouped according to
their functional class, based on their clinical characteristics
(Table 1). Most patients in functional classes II to IV had
received cardiac glycosides, diuretic drugs or coronary vasodi-
lating agents. All serum creatinine and aminotransferases
levels were within the normal range. Sixty-two age- and
gender-matched subjects with no disease and no medication
were included as a control group (Table 1).
All subjects studied here gave their informed consent to the
study, which was approved by the local ethics committee on
human research (Gifu University).
Blood sampling. Peripheral venous blood samples were
taken slowly from an antecubital vein and were transferred to
chilled disposable tubes containing 2-natrium-ethylenediamine
tetraacetic acid (1.5 mg/ml). Then, the disposable tubes were
promptly centrifuged at 4°C, and aliquots of plasma were
immediately stored at 280°C until analyzed.
In eight patients with CHF, a second plasma sample to
measure the reproducibilities of plasma sFas and sFas-L levels
was taken 1 day after the first sample. All patients were
reevaluated for the severity of CHF 6 months after the first
plasma sample was taken, and plasma sFas levels were remea-
sured.
To determine the main site of sFas expression, blood
samples were taken from the pulmonary artery, coronary sinus,
superior vena cava, right or left renal vein and femoral artery,
in 8 patients in functional class II or III, using a 7F Swan-Ganz
catheter and a 6F Judkins-type catheter for the right coronary
artery.
sFas and sFas-L assay by enzyme-linked immunosorbent
assay. We have developed and characterized a highly sensitive
enzyme-linked immunosorbent assay (ELISA) for plasma sFas
(32). Polystyrene plates were precoated with rabbit immuno-
globulin (IgG) for anti-human Fas synthetic peptide (amino
Abbreviations and Acronyms
CHF 5 congestive heart failure
ELISA 5 enzyme-linked immunosorbent assay
Fas 5 Fas/APO-1 receptor
Fas-L 5 Fas ligand
Ig 5 immunoglobulin
IL-6 5 interleukin-6
PBS 5 phosphate-buffered saline
sFas 5 soluble Fas
sFas-L 5 soluble Fas ligand
TNF 5 tumor necrosis factor
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acids 305 to 319), and each well was blocked with 1% bovine
serum albumin/phosphate-buffered saline (PBS). Plasma was
diluted to a ratio of 1:5 in PBS containing 0% normal rabbit
serum, and 100 ml of the diluted sample was applied to each
well. The wells were incubated with mild shaking (200 rpm) at
room temperature for 1 h. After the incubation, the wells were
washed with PBS containing 0.05% Tween 20, and 100 ml of
horseradish peroxidase conjugated anti-human Fas mouse
monoclonal antibodies developed by Yonehara et al. (18) was
added and incubated with shaking at room temperature for 1 h.
The wells were then washed with PBS containing 0.05% Tween
20 and incubated for 30 min with 100 ml of freshly prepared
tetramethylbenzidine (1.0 mmol/l) in 10 mmol/l citric acid
buffer, pH 5.5, containing hydrogen peroxide (3.5 mmol/l) in
each well. The reaction was terminated by the addition of
100 ml of 6 mol/liter phosphate. The absorbance was read at
450 nm using a microplate reader (SLT-210, Labinstruments,
Glodig, Austria). The results were calculated from the best-
fitting least-square parabola with an on-line microcomputer
(NEC 9801-VM2, NEC Co., Tokyo). All samples were assayed
in duplicate. The linear part of the calibration range was from
0.06 to 2.00 ng/ml, and the detection limit was 0.01 ng/ml. The
average within- and between-run coefficients of variation were
3.4% and 5.7%, respectively. Recovery of the sFas added to the
serum ranged between 93% and 118%.
Plasma levels of the sFas-L were also quantified by a
sandwich ELISA using NOK-1 (mouse IgG1, k) and NOK-3
(mouse IgM, k), monoclonal antibodies purified from mice
immunized through an intraperitoneal injection of human
Fas-L (L5178Y, mouse T lymphoma cell lines, kindly provided
by Dr. S. Yonehara, Kyoto University, Kyoto, Japan) (27).
Briefly, Immulon-2 plates (Dynatech Lab Inc.), were incubated
overnight with NOK-3 (10 mg/ml). After washing with 0.05%
Tween/PBS, the wells were blocked with a skim milk solution
(Block Ace, Snow Brand Milk Co., Sapporo, Japan) for 2 h at
37°C; 50 ml of the sample was added and incubated for 1 h at
room temperature; biotinylayed NOK-1 (5 mg/ml) containing
10% murine serum was then added and incubated for another
hour at room temperature; and, finally, 50 ml of ABC solution
(Vectastain ABC kit, Vector Lab. Inc.), was added and incu-
bated for 30 min at room temperature. The wells were
developed with 100 ml of 1 mg/ml of orthophenylenediamine in
50 mmol/liter citrate-phosphate buffer (pH 5.0) containing
0.03% H2O2 and stopped by the addition of 100 ml of 2N
H2SO4. The optical density at 490 nm was measured on a
microplate reader. Serial dilutions of purified sFas-L that had
been affinity purified from the human Fas-L/L5178Y superna-
tant in a NOK-1 column were used as the standard. The
detection limit of this assay was 0.2 ng/ml. We examined
whether measuring soluble Fas ligand was influenced by sFas.
We respectively incubated 1 or 10 ng/ml of human recombi-
nant sFas-L with 10-fold doses (10 or 100 ng/ml) of human
recombinant sFas at 37°C for 2 h. The result showed that the
levels of sFas-L were not influenced by sFas. Therefore,
increased levels of sFas do not mask an increase in sFas-L by
interfering with the assay.
The differences in sFas and sFas-L between the two assays
using plasma taken at the same time were 3.4 6 3.9% and
4.9 6 2.9%, respectively, and those between paired samples
taken at a 1-day interval were 5.0 6 2.2% and 4.3 6 2.0%,
respectively. These data were satisfactory and reliable.
Measurements of plasma TNF-alpha and IL-6 levels.
Plasma levels of TNF-alpha were measured using a sandwich
ELISA kit with two monoclonal anti-human TNF-alpha anti-
Table 1. Clinical Characteristics, Plasma Concentrations of sFas, sFas-L and Cytokines and
Hemodynamic Data
Control Group
(n 5 62)
NYHA Functional Class
I (n 5 20) II (n 5 20) III (n 5 15) IV (n 5 15)
Age (yrs) 62 6 5 63 6 4 66 6 2 64 6 4 66 6 5
M/F 43/19 14/6 13/7 10/5 11/4
Cause of CHF
DCM — 6 10 6 6
CAD — 10 6 5 6
VHD — 4 4 4 3
Plasma conc
sFas (ng/ml) 2.2 6 0.1 2.2 6 0.2 3.1 6 0.2*† 3.9 6 0.3*†‡ 5.1 6 0.6*†‡§
sFas-L (ng/ml) 0.43 6 0.01 0.44 6 0.01 0.49 6 0.02 0.44 6 0.02 0.48 6 0.02
TNF-alpha (pg/ml) 4.2 6 0.6 5.9 6 2.0 10.0 6 3.3 11.3 6 5.5 121.0 6 28.3*†‡§
IL-6 (pg/ml) 2.5 6 0.2 4.1 6 0.8 4.0 6 1.0 10.0 6 3.6 53.9 6 19.3*†‡§
Hemodynamic data
PAW (mm Hg) — 10 6 1 11 6 1 20 6 2†‡ 25 6 2†‡
CI (liters/min/per m2) — 3.1 6 0.1 3.0 6 0.2 2.3 6 0.1†‡ 2.0 6 0.1†‡
*p , 0.05 versus Control Group. †p , 0.05 versus New York Heart Association (NYHA) functional class I. ‡p , 0.05
versus functional class II. §p , 0.05 versus functional class III. Data presented are mean value 6 SEM or number of
patients. CAD 5 coronary artery disease; CHF 5 congestive heart failure; CI 5 cardiac index; conc 5 concentration;
DCM 5 dilated cardiomyopathy; F 5 female; IL-6 5 interleukin-6; M 5 male; PAW 5 pulmonary artery wedge
pressure; sFas 5 soluble Fas; sFas-L 5 soluble Fas ligand; TNF 5 tumor necrosis factor; VHD 5 valvular heart disease.
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bodies (No. 1121, Immunotech, Marseille, France). The
plasma levels reported for healthy subjects were ,5 pg/ml (33).
The sensitivity limit of the assay in the plasma was 5 pg/ml. No
cross-reactivity or interference with either TNF-beta or the p55
and p75 forms of the TNF receptor was observed. Intraassay
and Interassay coefficients of variation were 7.0% and 6.8%,
respectively.
Plasma levels of IL-6 were also measured using a two-step
sandwich ELISA kit with two monoclonal anti-human IL-6
antibodies and recombinant IL-6 standards (Human IL-6
ELISA Kit Fujirebio, Fujirebio Inc., Tokyo, Japan), as re-
ported by Yamagishi et al. (34). The sensitivity limit of the
assay was 3 pg/ml, and its analytic range was from 3 to 200
pg/ml. Its precision, reproducibility and sensitivity were satis-
factory (34). Reproducibility with the same plasma was 1.3%;
plasma IL-6 levels from 200 normal subjects were all ,3 pg/ml.
Right-sided cardiac catheterization. Right-sided cardiac
catheterization using a 7F Swan-Ganz thermodilution catheter
(Baxter Healthcare Corporation) was performed in all patients
for measurement of pulmonary artery wedge pressure and
cardiac output within 3 days before or after blood sampling,
according to standard techniques. Cardiac index was calculated
as the ratio of cardiac output to body surface area.
Statistical analysis. Plasma levels of sFas, sFas-L, TNF
and IL-6 and hemodynamic variables were compared among
patient groups and normal subjects by one-way analysis of
variance (Bonferroni/Dunn), and if the difference was signifi-
cant, a modified unpaired t test was used to assess which group
was significantly different. Correlations between plasma levels
of sFas or sFas-L and cytokines or hemodynamic variables
were examined using simple linear regression analysis by the
least-squares method, and differences between regression lines
were tested by analysis of covariance using sFas or sFas-L as a
dependent variable and either a hemodynamic or echocardio-
graphic variable as an independent variable. Results are ex-
pressed as mean value 6 SEM; p , 0.05 was regarded as
significant.
Results
Characteristics of patients and hemodynamic data. Table
1 shows the clinical characteristics and hemodynamic data for
the four groups of patients and the normal subjects. There
were no significant differences in age or gender ratio among
the five groups. All patient groups were similar with respect to
cause of heart failure (Table 1). Pulmonary artery wedge
pressure was not significantly different between functional
classes I and II but was significantly higher in functional classes
III and IV than in functional classes I and II. Cardiac index
decreased with increasing severity of CHF and was significantly
lower in functional classes III and IV than in functional classes
I and II (Table 1).
Plasma levels of sFas and sFas-L. There were no signifi-
cant differences in plasma levels of sFas-L between any of the
patient groups and normal subjects (Table 1). However, sFas
increased levels significantly with severity of CHF (Fig. 1).
Plasma levels of sFas were similar in normal subjects and
patients in functional classes I, but there were significant
differences between functional classes II, III and IV. Plasma
sFas levels in patients with CHF relative to those in normal
subjects were 1.0 in functional classes I, 1.4 in functional
classes II, 1.8 in functional classes III and 2.3 in functional
classes IV. The underlying cardiac disease in patients with
CHF was coronary heart disease, dilated cardiomyopathy or
valvular heart disease (Table 1). There was no significant
difference in plasma sFas levels among patients in functional
classes I to III and even among those in functional classes IV.
Plasma sFas levels were significantly higher in patients with an
elevated pulmonary artery wedge pressure (.18 mm Hg) and
a decreased cardiac index (,2.2 liters/min per m2 body surface
area) than in those with values in the normal ranges (Fig. 2).
All patients were reevaluated for functional classes and
plasma sFas levels 6 months after the first plasma sample was
taken, and their prognosis (survival or death) was evaluated.
Nine of 70 patients with CHF (1 of 15 in functional classes III;
8 of 15 in functional classes IV) died. Of patients in functional
classes III and IV, the functional classes improved in nine (four
in functional classes III, five in functional classes IV), wors-
ened in one in functional classes III and had not changed in the
other three (one in functional classes III, two in functional
classes IV). In patients in functional classes IV, there was no
significant difference in plasma sFas levels between the survi-
vors (5.7 6 0.9 ng/ml) and those who died (4.5 6 0.9 ng/ml, p 5
0.38). However, plasma levels of sFas tended to decrease in
patients with clinical improvement (baseline 5.2 6 0.8 ng/ml,
Figure 1. Plasma soluble Fas (sFas) levels in patients according to
New York Heart Association (NYHA) functional class. Note that
normal subjects and patients in functional classes I had similar plasma
levels of sFas, but significant differences are seen between patients in
functional classes II to and IV. Open circles 5 mean value 6 SEM.
*p , 0.05.
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6-month follow-up 4.3 6 0.5 ng/ml, p 5 0.07) but were similar
in those who had no change in functional classes (baseline
4.3 6 0.5 ng/ml, 6-month follow-up 4.7 6 0.3 ng/ml).
To determine the main site of sFas expression, blood
samples were taken from the pulmonary artery, coronary sinus,
superior vena cava, right or left renal vein and femoral artery
in eight patients in functional classes II or III. There were no
significant differences in sFas levels among the different sites:
3.6 6 0.4 ng/ml for the pulmonary artery; 3.7 6 0.3 ng/ml for
the coronary sinus; 3.3 6 0.5 ng/ml for the superior vena cava;
3.7 6 0.4 ng/ml for the right or left renal vein; and 3.4 6
0.5 ng/ml for the femoral artery.
Plasma levels of TNF-alpha and IL-6. Plasma levels of
both TNF-alpha and IL-6 increased significantly only in pa-
tients in functional classes IV. There was no correlation
between plasma levels of sFas and TNF-alpha or IL-6 (Table 1).
Discussion
The present study revealed that in patients with chronic
CHF, plasma sFas-L levels did not increase, but plasma sFas
levels increased relative to the severity of functional class.
Measurement of plasma sFas-L and sFas levels. The
plasma level of sFas-L was 0.43 6 0.01 ng/ml in normal
subjects. There was no evidence of an increase in sFas-L in
patients with CHF in this study.
Using the ELISA method we developed, the sFas level in
the plasma of 155 healthy subjects was 2.3 6 0.1 ng/ml; it was
higher in men than in women and increased according to age
(32). The precision, recovery and linearity were all excellent.
The assay was not affected by possible interfering substances.
In this study, the sFas level in the plasma was also 2.2 6
0.1 ng/ml in 62 normal subjects. The variation between results
from the same samples and between samples taken 1 day later
were also very small, and the data were reliable. However, the
sFas levels in the plasma were much lower than those previ-
ously reported by Cheng et al. (23) (,30 ng/ml), although the
rate of elevation in CHF (approximately twofold) was similar
to that in patients with systemic lupus erythematosus and B-
and T-cell leukemias and lymphoma, which they reported
(23,24). The reason for this difference is unknown at present.
However, some possible explanations are 1) because they also
used an ELISA system, there seems to be no major differences
between the assays. Therefore, differences in the standard and
the specificity of antibodies against sFas are likely, but they are
not described in detail. 2) There may be population differ-
ences, but this is not likely because the difference between their
results and ours are more than 10-fold. Their study was also a
small study (n 5 10), and they did not mention gender and age
differences in their healthy subjects.
Plasma sFas and CHF. In the present study, plasma sFas
increased significantly, even in patients in functional classes II,
and was highest in those in functional classes IV. Plasma sFas
also increased significantly in patients with elevated pulmonary
artery wedge pressure and a depressed cardiac index but
tended to decrease in patients with an improvement in func-
tional classes (p 5 0.07) and remained the same in patients
with no change in functional class. Plasma sFas levels were
similar between survivors and nonsurvivors. A significant ele-
vation of plasma sFas levels .2 SD of that in normal subjects
was seen in 20% of patients in functional classes II, 53% of
those in functional classes III and 67% of those in functional
classes IV. Plasma sFas levels varied considerably from those
in the normal range to very high levels, even in patients in
functional classes IV. There was no significant difference in
plasma sFas levels with regard to underlying cardiac disease
(coronary artery disease, dilated cardiomyopathy, valvular
heart disease).
Thus, the increase in plasma sFas occurs independently of
underlying cardiac disease but reflects the severity of CHF
despite the presence of limitations. Therefore, the increase in
plasma sFas may be related to the pathophysiologic mecha-
nisms of CHF, at least, in patients in whom plasma sFas levels
are elevated.
Increased plasma sFas and apoptosis in CHF. In CHF, the
heart cannot pump blood at a rate commensurate with the
requirements of the metabolizing tissue. Therefore, relative
hypoxia or ischemia, congestion, hypertrophy, cell death and
fibrosis occur in various organs, such as the heart, lungs, liver
and spleen. Progressive deterioration of left ventricular func-
tion is also a characteristic feature of CHF. This progressive
deterioration occurs despite the absence of intercurrent ad-
verse clinical events. Recent studies using canine heart failure
models and human dilated cardiomyopathy with advanced
CHF showed that ongoing myocyte loss due to apoptosis is
important in the pathogenesis (11,35). Although the factors
that may trigger apoptosis in the failed myocardium are
unclear, increased cytosolic calcium concentration, formation
of oxygen free radicals, temporary ischemia and hypoxia may
all trigger apoptosis (9,11,12,36). In patients with CHF, abnor-
malities of various apoptosis-related factors have been re-
Figure 2. Comparison of plasma soluble Fas (sFas) levels between
patients with and without elevated pulmonary artery wedge pressure
(PAW) (.18 mm Hg) and those with and without a decreased cardiac
index (CI) (,2.2 liters/min/per m2 body surface area). Open circles 5
mean value 6 SEM. *p , 0.05 versus normal subjects.
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ported. Levels of cytokines, such as plasma TNF-alpha, IL-1
and IL-6, all inducers of apoptosis, are elevated (14–17). The
cytolytic activity of TNF is mediated by Fas in animal models
(36).
In the present study, we found an elevation of approxi-
mately twice that of the normal range in plasma sFas, an
inhibitor of apoptosis, in patients with advanced CHF. As
Cheng et al. (23) described, sFas injected at approximately
twice the control level in mice is active in vivo and inhibits cell
apoptosis; the increased plasma sFas in CHF may have an
inhibiting effect against apoptosis. However, plasma sFas-L, an
inducer of apoptosis, was not increased in the present study.
To date, there have been no reports of overexpression of Fas
and Fas-L, inducers of apoptosis, in patients with CHF. In
addition, cells stimulated toward apoptosis might cleave and
release or synthesize sFas as a consequence of apoptosis. That
is, there is no evidence to suggest the Fas–Fas-L system
contributes to apoptosis in human CHF. Therefore, it remains
unknown whether the elevation of plasma sFas in CHF is
protective against apoptosis.
Recently, Wada et al. (37) reported that the nuclear factor
for IL-6 is activated on influenza virus infection of HeLa cells
through posttranslational modification, and that the modified
factor stimulates the transcription of the human Fas gene.
However, plasma levels of IL-6 were not related to plasma sFas
levels. Several investigators (9) have reported that hypoxia
induced expression of Fas messenger RNA in cultured neona-
tal rat cardiomyocytes, which suggests that hypoxia in CHF
may also induce an increase in sFas in humans. An alternative
explanation for our findings is that the increase in sFas is
indicative of ongoing “immune activation” in CHF.
It has been reported (30) that Fas is present in the heart,
thymus, liver, kidney, ovary and other organs. To determine
whether increased levels of sFas are released from the heart,
lung or kidney, we measured plasma levels in the coronary
sinus, superior vena cava, pulmonary artery, right or left renal
vein and femoral artery. The differences in plasma sFas among
these sampling sites were slight (from 0 to 0.4 ng/ml). How-
ever, plasma levels are determined both by rate of release and
half-life. The circulating half-life of sFas may be long or the
release rate may be very low such that it would not be
detectable as a difference in regional drainage.
Conclusions. Plasma levels of sFas increase in relation to
the severity of CHF. The increase in plasma sFas may be an
important role in the pathophysiology of CHF, although the
specific mechanism remains unclear.
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